Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis [Yahoo! Finance]
Organogenesis Holdings Inc. - Class A (ORGO)
Last organogenesis holdings inc. - class a earnings: 3/9 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Transformational opportunity for Organogenesis to enter large and growing pain management market with innovative therapy Will address critical unmet medical need for all knee OA patients, including the most severe, if approved CANTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that its Phase 3 randomized control trial evaluating the safety and efficacy of ReNu, a cryopreserved amniotic suspension allograft (ASA), for the management of symptoms associated with knee osteoarthritis (OA) achieved its primary endpoint upon the analysis of positive top line data. The study demonstrated a statistically significant reduction in knee OA pain at six months as assessed by the Western Ontario and McMaster Universities Arthritis Index pain scal
Show less
Read more
Impact Snapshot
Event Time:
ORGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORGO alerts
High impacting Organogenesis Holdings Inc. - Class A news events
Weekly update
A roundup of the hottest topics
ORGO
News
- Organogenesis Holdings Inc. (NASDAQ:ORGO) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Organogenesis (ORGO) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Organogenesis Holdings Inc. Reports First Quarter 2024 Financial ResultsGlobeNewswire
- Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee OsteoarthritisGlobeNewswire
ORGO
Earnings
- 5/9/24 - Beat
ORGO
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 4/29/24 - Form 3
- ORGO's page on the SEC website